InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $3.420 -0.55 (-13.85%)+
Announcement
Release
1 Jun 2026 9:31AM
Price at Release
$3.970
Full Release
download
Summary
4DMedical Limited, a leader in respiratory imaging technology, announced its European expansion through the acquisition of contextflow GmbH, an Austrian company specializing in lung cancer screening and advanced thoracic imaging. This acquisition provides 4DMedical with immediate commercial and clinical presence in Europe, leveraging contextflow's existing market infrastructure, including CE-marked products and established clinical partnerships. The deal, valued at approximately A$18.56 million in cash and shares, includes additional earnout options contingent on achieving specific milestones. The move positions 4DMedical to accelerate the deployment of its CT:VQ™ technology across Europe, enhancing its global operational footprint and supporting its goal of becoming a leader in advanced lung analysis software.
Key Points
  • 4DMedical establishes an immediate European commercial and clinical platform.
  • Acquisition of Austrian-based contextflow for lung cancer screening expertise.
  • Transaction includes upfront payment and contingent earnout options.
  • Provides immediate market access and scalable foundation for European expansion.
  • Enhances 4DMedical's global presence across North America, Europe, and ANZ.
  • Strengthens product offering with AI-based lung cancer detection tools.
  • Introduces CT:VQ™ technology to the European market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.